
Key Points
- 01Pfizer targets high single-digit growth after a two-year loss-of-exclusivity period
- 02Launch products grew 32% and generate about $15–16 billion annualized revenue
- 03Planned monthly obesity drug Gutspeed is slated for launch in about two years
- 04Pfizer reports $7.2 billion in net savings and has announced a further $1.5 billion
Pfizer’s roadmap beyond its patent cliff
Pfizer CEO Albert Bourla set out a detailed strategy for returning to high single-digit growth once the company moves past its current loss-of-exclusivity period, which he expects to last about two more years. Speaking at the Jefferies London and Global Healthcare Conference on November 17, 2026, he said Pfizer is leaning on acquisitions, new product launches, cost reductions and an expanded pipeline to support growth into the next decade.
Recently launched medicines grew 32% in the latest quarter and now contribute approximately $15 billion to $16 billion in annualized revenue. Bourla characterized this cohort as a key buffer during the loss-of-exclusivity phase and a foundation for growth beyond it.
Obesity franchise centered on monthly dosing
A central element of Pfizer’s future growth plan is its obesity portfolio, anchored by a planned monthly injectable drug called Gutspeed. The medicine is designed for monthly dosing rather than weekly injections, with Bourla citing market research that shows a strong and clear consumer preference for monthly treatment.
Pfizer expects to launch the obesity drug in about two years, positioning it as part of a broader franchise rather than a standalone asset. The company is running switch studies to evaluate whether patients on weekly GLP-1 medicines can maintain weight loss after moving to monthly dosing. Bourla said Pfizer is confident it can achieve comparable efficacy and tolerability with monthly administration, subject to confirmation by clinical studies.
He also pointed to Pfizer’s long-standing primary care sales force in the United States and its direct-to-consumer marketing experience, including lessons from VIAGRA, as potential advantages in commercializing obesity treatments.
Oncology and immunology pipeline priorities
Bourla identified oncology as a major focus as breast cancer drug IBRANCE and prostate cancer treatment XTANDI face patent expirations. Pfizer is advancing CDK4 programs in breast cancer and is developing the prostate cancer candidate mevrometostat as a key follow-on asset, with Bourla describing its market opportunity as about four times larger than XTANDI’s because Pfizer holds global rights.
In multiple myeloma, Bourla highlighted ELREXFIO as an area where Pfizer aims to gain leadership. In inflammation and immunology, he underscored a trispecific atopic dermatitis program that has moved into a robust Phase 3 program, including head-to-head studies against DUPIXENT. He said that if the data continue to support it, the trispecific could become a “mega blockbuster,” and that follow-on trispecific molecules are being explored for other indications.
Cost savings, development acceleration and AI
Pfizer has invested about $80 billion in acquisitions following the COVID-19 period, a figure Bourla contrasted with roughly $40 billion by its second-largest competitor, as part of a strategy to build new platforms. At the same time, the company has delivered $7.2 billion in net savings, expected to be fully realized by year-end, and has announced an additional $1.5 billion in savings.
Bourla said Pfizer’s development engine has accelerated, with 20 Phase 3 studies started this year, nearly double the number begun the year before. The company has initiated head-to-head studies in atopic dermatitis and is studying drug–drug interactions in its STAT6 program ahead of larger Phase 3 trials. He described artificial intelligence as an important tool for improving productivity, with its first impact likely in enabling functions rather than core research.
Looking ahead, Bourla said Pfizer expects the current loss-of-exclusivity cycle to run through 2028 but is planning for growth thereafter. He also noted that pricing pressure and lower-cost, fast-moving Chinese biotech rivals could reshape the competitive landscape, reinforcing Pfizer’s focus on doing more with less.
Key Takeaways
- 01Pfizer intends to offset upcoming patent losses with a combination of high-growth launches, a deep late-stage pipeline and significant cost savings.
- 02A planned monthly obesity drug, supported by switch studies and commercial infrastructure, is positioned as a major new platform rather than a single product bet.
- 03Oncology and immunology assets such as mevrometostat, ELREXFIO and the trispecific atopic dermatitis program are central to restoring growth as legacy cancer drugs lose exclusivity.
References
- https://www.marketbeat.com/instant-alerts/event-pfizer-ceo-sees-growth-beyond-patent-cliff-highlights-monthly-obesity-drug-ambitions-2026-11-17/?.tsrc=rss
- https://in.investing.com/news/stock-market-news/pfizer-at-jefferies-global-healthcare-conference-pipeline-ai-and-loe-93CH-5709076
- https://uk.investing.com/news/stock-market-news/pfizer-at-jefferies-global-healthcare-conference-pipeline-ai-and-loe-93CH-4987053
- https://www.investing.com/news/transcripts/pfizer-at-jefferies-global-healthcare-conference-pipeline-ai-and-loe-93CH-5032102